Generic Name and Formulations:
Methenamine 81mg, sodium biphosphate 40.8mg, phenyl salicylate 32.4mg, methylene blue 10.8mg, hyoscyamine sulfate 0.12mg; tabs.
Indications for URELLE:
Treatment of symptoms of irritative voiding. Relief of local symptoms due to lower UTIs or diagnostic procedures.
1 tab 4 times daily.
≤6yrs: not recommended. >6yrs: individualize dose.
Cardiac disease. GI or GU obstruction. Glaucoma. Myasthenia gravis.
Maintain acid urine and adequate hydration. Gastric ulcers. Discolors urine/feces. Discontinue if rapid pulse, dizziness, or blurred vision occurs. Elderly. Pregnancy (Cat.C). Nursing mothers.
Allow at least 2 hours after ketoconazole. May be potentiated by antimuscarinics, antimyasthenics, MAOIs, opioids. May be antagonized by thiazide diuretics, urinary alkalinizers. Separate dosing of antacids, antidiarrheals by 1 hour. May reduce absorption of other drugs. Sulfonamides precipitate with formaldehyde in urine; avoid concomitant use.
Urinary tract analgesic/antispasmodic/antiseptic.
Rapid pulse, flushing, blurred vision, dizziness, shortness of breath, acute urinary retention, difficult micturition, dry mouth, nausea, vomiting.
Neurology Advisor Articles
- Clarifying Cardiovascular Risk in Migraine
- More Evidence Supports Benefits of Cannabidiol for Treatment-Resistant Epilepsy
- Parkinson Disease Symptom Fluctuations Well-Managed With Adaptive Deep Brain Stimulation
- Monthly Erenumab Reduces Frequency of Episodic Migraine
- Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS
- Tamsulosin Associated With Dementia Risk in Older Patients With BPH
- FDA Approves Blood Test to Assess Concussion
- Gait Difficulty in Parkinson Disease May Be Associated With More Progressive Disease Course
- Tau PET a Useful Biomarker for Alzheimer Disease Risk and Progression
- Multiple Sclerosis Drug Zinbryta Withdrawn From the Market
- Undifferentiated Headaches Common in Children, Adolescents
- Smoking Associated With Increased Relapse Rate in Interferon Beta-Treated Relapsing-Remitting MS
- Frontotemporal Dementia, Frontotemporal Lobar Degeneration Symptoms More Common Later in Life
- No Reduction in Cerebral Perfusion With Intensive Blood Pressure Lowering
- Successful Delirium Prevention in Critically Ill With Dexmedetomidine